Company intelligence / Profile preview

Nippon Boehringer Ingelheim

Shinagawa, Tokyo, Japan

Ownership: Private
Employees: ~2700
Development stage: Other

Overview

Nippon Boehringer Ingelheim is the Japanese subsidiary of the global Boehringer Ingelheim group. It maintains a robust commercial portfolio and clinical pipeline in Japan, with significant recent success in the expansion of Jardiance for heart failure and chronic kidney disease, and the launch of Spevigo for generalized pustular psoriasis. The company operates a major R&D center in Kobe and a manufacturing facility in Yamagata, contributing to global development programs in oncology, respiratory, and cardiometabolic diseases.

Therapeutic areas: NephrologyEndocrinologyCardiovascularDermatologyPsychiatryPulmonologyRheumatologyOncology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Pharma

Partnerships

Eli LillyAbbVieInventivaKyoto University

Beyond the preview

Go deeper on Nippon Boehringer Ingelheim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nippon Boehringer Ingelheim.

Explore the full profile